

RNS Number : 1840J  
Wellnex Life Limited  
19 May 2025

**Wellnex Life Limited (ASX/AIM:WNX)**

**Issue of Shares**

Wellnex Life Limited ("**Wellnex**" or the "**Company**") (ASX/AIM:WNX), an innovative consumer healthcare business with a track record for developing, licensing, and marketing products and brands to customers in the growing healthcare market segment, announces that it has issued 646,153 new ordinary shares of no par value each in the Company ("Ordinary Shares") at a reference price of A 0.65 per share, in settlement of fees in respect of an undertaking provided by Barclay Pearce Capital Investment Pty Limited to the Company at the time of its admission to AIM.

Further details in respect of the undertaking are set out in the Company's Admission Document.

**Admission and Total Voting Rights**

Application has been made to the London Stock Exchange for admission of the 646,153 Ordinary Shares to trading on AIM. It is expected that admission will become effective and dealings in the Ordinary Shares will commence on AIM at 8.00 a.m. on or around 22 May 2025.

The new Ordinary Shares will be issued fully paid and will rank *pari passu* in all respects with the Company's existing Ordinary Shares.

Following Admission, the Company's issued share capital will comprise of 67,771,528 Ordinary Shares, none of which are held in treasury. Accordingly, the figure of 67,771,528 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules and the provisions of the Company's constitution.

This AIM announcement has been authorised by the Board of Wellnex Life Limited (ASX/AIM:WNX).

For further information, please contact:

**Wellnex Life Limited (ASX:WNX)**  
George Karafotias or Zack Bozinovski  
Joint Chief Executive Officers  
P: +61 3 8399 9419  
E: [george.k@Wellnexlife.com.au](mailto:george.k@Wellnexlife.com.au)

**Reach Markets**  
T: 1300 805 9419  
E: [IR@reachmarkets.com.au](mailto:IR@reachmarkets.com.au)

UK Investors

Strand Hanson (Financial & Nominated Advisor)  
James Harris / Richard Johnson / Robert Collins Tel: +44 (0) 20 7409 3494

Orana Corporate LLP (Joint Broker) [swykeham@oranacorp.com](mailto:swykeham@oranacorp.com)  
Sebastian Wykeham

S.P. Angel Corporate Finance LLP (Joint Broker) Tel: +44 (0)20 3470 0470  
David Hignell / Vadim Alexandre

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCQKLBFEELBBBE